Dose Ranging Study of Tolperisone in Acute Muscle Spasm of the Back

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Feb 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolperisone (Primary)
Indications Back pain; Spasm
Focus Therapeutic Use
Acronyms STAR
Sponsors Neurana Pharmaceuticals

Most Recent Events

23 Nov 2020 According to a Neurana Pharmaceuticals media release, Srinivas Nalamachu, (M.D., Adjunct Associate Professor, Kansas City University of Medicine and Biosciences) is the lead author.
23 Nov 2020 According to a Neurana Pharmaceuticals media release, results from this dose-ranging Phase 2 study were published in the Journal of Pain Research.
23 Nov 2020 Results presented in a Neurana Pharmaceuticals media release.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight